Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines

Vaccine

Volumn 32, Issue 3, 2014, Pages 338-344

  Marshall, Helen ^a,b,c   Clarke, Michelle ^a,b   Sullivan, Thomas ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Adolescents; Adverse events; Immunisation policy; Meningococcal B; Parental attitudes; Vaccine

Indexed keywords

MENINGOCOCCUS B VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; COMMUNITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEAR; FEMALE; FEVER; GENERAL PRACTITIONER; HEALTH CARE SURVEY; HUMAN; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; INTERVIEW; MALE; MIDDLE AGED; PARENTAL ATTITUDE; PRIORITY JOURNAL; SOCIAL ATTITUDE; VACCINATION REACTION; VERY ELDERLY; YOUNG ADULT;

ABS; ADOLESCENTS; ADVERSE EVENTS; AUSTRALIAN BUREAU OF STATISTICS; CD; CI; COLLECTORS' DISTRICTS; CONFIDENCE INTERVAL; EU; EUROPEAN UNION; GENERAL PRACTITIONER; GP; IMD; IMMUNISATION POLICY; INVASIVE MENINGOCOCCAL DISEASE; MEN ABCWY; MEN B; MENINGOCOCCAL B; MENINGOCOCCAL SEROGROUP A, B, C, W, Y; MENINGOCOCCAL SEROGROUP B; ODDS RATIOS; OR; PARENTAL ATTITUDES; POPULATION RESEARCH AND OUTCOMES STUDIES; PROS; SA; SEIFA; SOCIO ECONOMIC INDEX FOR AREAS; SOUTH AUSTRALIA; VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CROSS-SECTIONAL STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS AS TOPIC; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RISK ASSESSMENT; YOUNG ADULT;

EID: 84890984492     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.042     Document Type: Article

References (27)

1. Marshall H.S., Richmond P.C., Nissen M., Jiang Q., Anderson A.S., Jansen K.U., et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial. PIDJ 2012, 31(10):1061-1068.
2. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12(8):597-607.
3. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381(9869):825-835.
4. Findlow H., Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine ACWY-TT. Adv Ther 2013, 30(5):431-458.
5. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9/10):1087-1096.
6. Snape M. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(2):B67-B72.
7. ® meningococcal B vaccine in the UK 2013, Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_state ment_on_meningococcal_B_vaccination_for_web.pdf [accessed 28.10.13].
8. ® 2011, Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-nov11-positive [cited 09.08.13].
9. Marshall H., Ryan P., Roberton D., Baghurst P. A cross sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust N Z J Public Health 2007, 31(3):235-242.
10. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
11. PROS Health omnibus survey methodology brief report: population research and outcomes studies unit 2012, The University of Adelaide, Adelaide, South Australia.
12. Australian Bureau of Stastistics Socio-Economic Indexes for Areas (SEIFA) - technical paper, 2006 2008, Canberra, Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/2033.0.55.0012006OpenDocument [accessed 10.08.12].
13. SAS Institute Inc. SAS Version 9.3 2011, SAS Institute Inc., Cary, NC.
14. Australian Bureau of Statistics Census of population and housing, 2011 census 2011, Available from: http://www.abs.gov.au/cdataonline.
15. Parelli A., Gold M., Marshall H., Braunack-Mayer A., Baghurst P. Parental perspectives of vaccine safety and experience of adverse events following immunisation. Vaccine 2013, 31(16):2067-2074.
16. Prymula R., Vesikari T., Esposito S., Kohl I., Ypma E., Toneatto D., et al. Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup b vaccine (4CMenB) - exploration of a two dose schedule. Poster presented at: 29th annual meeting of the European Society for Paediatric Infectious Disease (ESPID) 2011.
17. Prymula R., Siegrist C.-A., Chlibek R., Zemlickova H., Vackova M., Smetana J., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374(9698):1339-1350.
18. Novartis Vaccines and Diagnostics S.r.l. BEXSERO [European public assessment report product information]. Siena, Italy, 2012.
19. Gerend M.A., Shepherd M.A., Lustria M.L. Increasing human papillomavirus vaccine acceptability by tailoring messages to young adult women's perceived barriers. Sex Transm Dis 2013, 40((5) May):401-405.
20. Kharbanda E.O., Vargas C.Y., Castano P.M., Lara M., Andres R., Stockwell M.S. Exploring pregnant women's views on influenza vaccination and educational text messages. Prev Med 2011, 52:75-77.
21. Flood E.M., Rousculp M.D., Ryan K.J., Beusterien K.M., Divino V.M., Toback S.L., et al. Parents' decision-making regarding vaccinating their children against influenza: a web-based survey. Clin Ther 2010, 32(8):1448-1467.
22. Zimet G. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 2005, 37:S17-S23.
23. Woodlin K.A., Rodewaold L.E., Humiston S.G., Carges M.S., Schaffer S.J., Szilagi P.G. Are children becoming pincushions from immunisationα. Arch Pediatr Adolesc Med 1995, 149:845-849.
24. Madlon-Kay D.J., Harper P.G. Too many shotsα Parent, nurse and physician attitudes toward multiple simultaneous childhood vaccinations. Arch Fam Med 1994, 3:610-617.
25. Thomas M.L., Bodnar P.Z., O'Donovan J.C., Gouel E.G., Walcher J.R. Halsey NA Parental knowledge and choice regarding live and inactivated poliovirus vaccines. Arch Pediatr Adolesc Med 1997, 151((8) August):809-812.
26. Kolasa M.S., Bisgard K.M., Prevots D.R., Desai S.N., Dibling K. Parental attitudes toward multiple poliovirus injections following a provider recommendation. Public Health Rep 2001, 116(4):282-288.
27. United States National Institutes of Health ClinicalTrials.gov - safety and immunogenicity of different meningitis vaccine formulations in adolescents and young adults 2013, Available from: http://clinicaltrials.gov/ct2/show/NCT01272180 [cited 20.08.13].